<?xml version='1.0' encoding='UTF-8'?><codeBook xmlns="ddi:codebook:2_5" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="ddi:codebook:2_5 https://ddialliance.org/Specification/DDI-Codebook/2.5/XMLSchema/codebook.xsd" version="2.5"><docDscr><citation><titlStmt><titl>Multi-Country Analysis of Treatment Costs for HIV/AIDS (MATCH): Unit costing at 161 Representative Facilities in Ethiopia, Malawi, Rwanda, South Africa and Zambia</titl><IDNo agency="DOI">doi:10.7910/DVN/SAL1TO</IDNo></titlStmt><distStmt><distrbtr source="archive">Harvard Dataverse</distrbtr><distDate>2012-09-17</distDate></distStmt><verStmt source="archive"><version date="2013-06-11" type="RELEASED">6</version></verStmt><biblCit>2012, "Multi-Country Analysis of Treatment Costs for HIV/AIDS (MATCH): Unit costing at 161 Representative Facilities in Ethiopia, Malawi, Rwanda, South Africa and Zambia", https://doi.org/10.7910/DVN/SAL1TO, Harvard Dataverse, V6</biblCit></citation></docDscr><stdyDscr><citation><titlStmt><titl>Multi-Country Analysis of Treatment Costs for HIV/AIDS (MATCH): Unit costing at 161 Representative Facilities in Ethiopia, Malawi, Rwanda, South Africa and Zambia</titl><IDNo agency="DOI">doi:10.7910/DVN/SAL1TO</IDNo></titlStmt><rspStmt><AuthEnty>N/A</AuthEnty></rspStmt><prodStmt><producer abbr="CHAI">Clinton Health Access Initiative</producer><prodDate>2012</prodDate></prodStmt><distStmt><distrbtr source="archive">Harvard Dataverse</distrbtr><depDate>2012-09-17</depDate><distDate>2012</distDate></distStmt><holdings URI="https://doi.org/10.7910/DVN/SAL1TO"/></citation><stdyInfo><subject><keyword>HIV, AIDS, Africa, Treatment Costs, Health Facilities</keyword></subject><abstract date="2012">&lt;p>&lt;b>Background&lt;/b>&lt;/p>  &lt;p>Today’s uncertain funding landscape threatens to halt progress towards global HIV/AIDS treatment and prevention goals. Improving the efficiency of HIV/AIDS spending is essential to effectively allocate existing funds and promote additional investment. Prior research focused on efficiency opportunities in ART, however recent and representative data on ART costs were limited.&lt;/p>  &lt;p>&lt;b>Methods and Findings&lt;/b>&lt;/p>  &lt;p>Comprehensive data on twelve months of ART costs w
ere collected at 161 representative facilities across five countries. Sites were selected using stratified random sampling. Patient characteristics and treatment outcomes were measured by reviewing 100 randomly-selected charts per facility.
&lt;/p>  &lt;p>ART costs were significantly lower than expected, averaging $200 per patient-year in low- and lower-middle income countries. Costs in South Africa were higher at $682 per patient-year. Main cost components were ARVs and personnel, together comprising more than 70% of costs. Facilities demonstrated the ability to keep patients alive and on treatment at these cost levels, with relatively low average annual attrition rates for established patients, ranging from 2 - 8%.  Retention rates for
new patients were highly variable and strongly correlated with CD4 count at initiation.
&lt;/p>  &lt;p>&lt;b>Conclusions&lt;/b>&lt;/p>  &lt;p>This study provides new evidence that aggressive scale-up of high-quality treatment in developing countries is possible and sustainable.  The low cost of ART should allay concerns about incurring a prohibitively expensive “treatment mortgage” through aggressive scale-up.   Additionally, there has been a significant global focus on driving savings by optimizing service delivery design and it appears as though significant savings are unlikely in facility-level A
RT costs. Optimization efforts should instead focus on treatment costs outside the facility and program costs unrelated to treatment. In South Africa, and likely other upper-middle income countries, optimizing ART service delivery will generate savings and should be pursued. Finally, across countries, there are clear opportunities to improve patient outcomes without substantially increasing cost, the most prominent of which is better using the money already being spent on pre-ART to more effectively drive earlier initiation of treatment.
&lt;/p>  &lt;p>&lt;b>Funding&lt;/b>&lt;/p>  &lt;p>The Bill and Melinda Gates Foundation&lt;/p></abstract><sumDscr><timePrd cycle="P1" event="start" date="2009">2009</timePrd><timePrd cycle="P1" event="end" date="2011">2011</timePrd><collDate cycle="P1" event="start" date="2010">2010</collDate><collDate cycle="P1" event="end" date="2010">2010</collDate><geogCover>Ethiopia, Malawi, Rwanda, South Africa and Zambia</geogCover><geogCover>Africa</geogCover><dataKind>HIV/AIDS Health Facility and Patient Data</dataKind></sumDscr></stdyInfo><method><dataColl><sources/></dataColl><anlyInfo/></method><dataAccs><setAvail/><useStmt/><notes type="DVN:TOU" level="dv">&lt;a href="http://creativecommons.org/publicdomain/zero/1.0">CC0 1.0&lt;/a></notes></dataAccs><othrStdyMat><relPubl><citation><titlStmt><titl>Tagar, Elya, Maaya Sundaram, Kate Condliffe, Mead Over, Blackson Matatityo, Frank Chimbwandira, Ben Chilima, Robert Mwanamanga, Crispin Moyo, Bona Mukosha Chitah, Jean Pierre Nyemazi, Yibeltal Assefa, Yogan Pillay, Lauren Shear, Mary Dain, Raphael Hurley, Ritu Kumar, Thomas McCarthy, Parul Batra, and Dan Gwinnell. "Multi-Country Analysis of Treatment Costs for HIV/AIDS (MATCH): Unit costing at 161 Representative Facilities in Ethiopia, Malawi, Rwanda, South Africa and Zambia." New York, New York: Clinton Health Access Initiative, 2012. Print.</titl></titlStmt><biblCit>Tagar, Elya, Maaya Sundaram, Kate Condliffe, Mead Over, Blackson Matatityo, Frank Chimbwandira, Ben Chilima, Robert Mwanamanga, Crispin Moyo, Bona Mukosha Chitah, Jean Pierre Nyemazi, Yibeltal Assefa, Yogan Pillay, Lauren Shear, Mary Dain, Raphael Hurley, Ritu Kumar, Thomas McCarthy, Parul Batra, and Dan Gwinnell. "Multi-Country Analysis of Treatment Costs for HIV/AIDS (MATCH): Unit costing at 161 Representative Facilities in Ethiopia, Malawi, Rwanda, South Africa and Zambia." New York, New York: Clinton Health Access Initiative, 2012. Print.</biblCit></citation></relPubl></othrStdyMat></stdyDscr><otherMat ID="f2437571" URI="https://dataverse.harvard.edu/api/access/datafile/2437571" level="datafile"><labl>1. Facility Costing Global Study Protocol.doc</labl><txt>Costing study protocol.</txt><notes level="file" type="DATAVERSE:CONTENTTYPE" subject="Content/MIME Type">application/msword</notes></otherMat><otherMat ID="f2431202" URI="https://dataverse.harvard.edu/api/access/datafile/2431202" level="datafile"><labl>2. ART Unit Costing Dataset Overview.docx</labl><txt>Overview of the dataset provided from the costing study.</txt><notes level="file" type="DATAVERSE:CONTENTTYPE" subject="Content/MIME Type">application/vnd.openxmlformats-officedocument.wordprocessingml.document</notes></otherMat><otherMat ID="f2437572" URI="https://dataverse.harvard.edu/api/access/datafile/2437572" level="datafile"><labl>3. DatStat Data Dictionary.xls</labl><txt>Data dictionary defining variables utilized in surveys during data collection.</txt><notes level="file" type="DATAVERSE:CONTENTTYPE" subject="Content/MIME Type">application/vnd.ms-excel</notes></otherMat><otherMat ID="f2431206" URI="https://dataverse.harvard.edu/api/access/datafile/2431206" level="datafile"><labl>4. Four Countries_Aggregated Facility Level Patient Data.xlsx</labl><txt>Aggregated Facility Level data for four countries in costing study. Requires approval from individual countries' Ministries (Departments) of Health for access.</txt><notes level="file" type="DATAVERSE:CONTENTTYPE" subject="Content/MIME Type">application/vnd.openxmlformats-officedocument.spreadsheetml.sheet</notes></otherMat><otherMat ID="f2431207" URI="https://dataverse.harvard.edu/api/access/datafile/2431207" level="datafile"><labl>5. Four Countries_Costing Data.xlsx</labl><txt>Costing data for four countries in costing study. Open access.</txt><notes level="file" type="DATAVERSE:CONTENTTYPE" subject="Content/MIME Type">application/vnd.openxmlformats-officedocument.spreadsheetml.sheet</notes></otherMat><otherMat ID="f2433006" URI="https://dataverse.harvard.edu/api/access/datafile/2433006" level="datafile"><labl>6. Individual Patient Data.xlsx</labl><txt>Individual patient data for all countries in costing study. Requires approval from individual countries' Ministries (Departments) of Health for access.</txt><notes level="file" type="DATAVERSE:CONTENTTYPE" subject="Content/MIME Type">application/vnd.openxmlformats-officedocument.spreadsheetml.sheet</notes></otherMat><otherMat ID="f2431210" URI="https://dataverse.harvard.edu/api/access/datafile/2431210" level="datafile"><labl>7. Standard Deck Short.pptx</labl><txt>Presentation with overview of results from costing study.</txt><notes level="file" type="DATAVERSE:CONTENTTYPE" subject="Content/MIME Type">application/octet-stream</notes></otherMat><otherMat ID="f2431208" URI="https://dataverse.harvard.edu/api/access/datafile/2431208" level="datafile"><labl>8. MATCH Journal Article Placeholder.docx</labl><txt>Journal article describing results from costing study.</txt><notes level="file" type="DATAVERSE:CONTENTTYPE" subject="Content/MIME Type">application/vnd.openxmlformats-officedocument.wordprocessingml.document</notes></otherMat><otherMat ID="f2431209" URI="https://dataverse.harvard.edu/api/access/datafile/2431209" level="datafile"><labl>9. Raw Facility Level Data.xlsx</labl><txt>Raw data file. Restricted access.</txt><notes level="file" type="DATAVERSE:CONTENTTYPE" subject="Content/MIME Type">application/vnd.openxmlformats-officedocument.spreadsheetml.sheet</notes></otherMat></codeBook>